Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in California: - Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente South Bay — Harbor City, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in California: - Fremont - Rideout Cancer Center — Marysville, California
- VA Palo Alto Health Care System — Palo Alto, California
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in California: - Research Site — Duarte, California
- Research Site — Fullerton, California
- Research Site — La Jolla, California
- Research Site — Los Alamitos, California
- Research Site — Orange, California
Phase 3 Recruiting Academic/Other
This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …
Sponsor: NRG Oncology
NCT ID: NCT07441681
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in California: - Site #0107 — La Jolla, California
- Site #0106 — Los Angeles, California
- Site#0144 — Sacramento, California
- Site #0130 — San Francisco, California
- Site #0150 — Stanford, California
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in California: - Providence St Jude Medical Center — Fullerton, California
- Scripps Health — La Jolla, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California, Los Angeles UCLA — Los Angeles, California
- Valkyrie Clinical Trials Murrieta — Murrieta, California
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in California: - Site 36 — La Jolla, California
- Site 27 — Los Angeles, California
- Site 16 — Palo Alto, California
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in California: - GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Solvang, California
- GSK Investigational Site — Stockton, California
- GSK Investigational Site — Torrance, California
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in California: - City of Hope — Duarte, California
- University of California at San Diego Moores Cancer Center — La Jolla, California
- Memorial Radiation Oncology Medical Group Laguna Hills — Laguna Hills, California
- UCLA Hematology Oncology — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in California: - California Research Institute — Los Angeles, California
- UCLA Cancer Care — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
Phase 3 Recruiting Industry
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…
Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Sites in California: - City of Hope — Duarte, California
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in California: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
- Local Institution - 2114 — La Jolla, California
- Local Institution - 2121 — Long Beach, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in California: - City of Hope — Duarte, California
- Los Angeles Cancer Network — Glendale, California
- California Research Institute — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Valkyrie Clinical Trials — Murrieta, California
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in California: - City of Hope — Duarte, California
- UC IRVINE Health — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in California: - The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, San Francisco (UCSF) — San Francisco, California
Phase 2 Recruiting Industry
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in California: - University of California Los Angeles — Los Angeles, California
- Samuel Oschin Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in California: - City of Hope — Duarte, California
- City of Hope, Irvine — Irvine, California
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in California: - USA06-0 — Los Angeles, California
- USA16-0 — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in California: - University of California at San Diego Moores Cancer Center — La Jolla, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in California: - University of California, Davis Comprehensive Cancer Center — Sacramento, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California